| Dr Jasmin R Cabrera, MD | |
|
3740 Utica Ridge Rd, Suite B, Bettendorf, IA 52722-1657 | |
| (563) 344-7400 | |
| (563) 359-9395 |
| Full Name | Dr Jasmin R Cabrera |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 3740 Utica Ridge Rd, Bettendorf, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003086364 | NPI | - | NPPES |
| 036119880 | Medicaid | IL | |
| 72295 | Other | IA | WELLMARK |
| 37559 | Other | IA | STATE OF IOWA |
| 036.119880 | Other | IL | STATE LICENSE |
| 349150 | Other | IA | COVENTRY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036.119880 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trinity - Rock Island | Rock island, IL | Hospital |
| Trinity - Bettendorf | Bettendorf, IA | Hospital |
| Genesis Medical Center-davenport | Davenport, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Physicians Clinic Medical Foundation | 8729992318 | 972 |
News Archive
Premier healthcare alliance's Gina Pugliese, vice president of Premier's Safety Institute, will share insights on safe injection practices to improve patient and worker safety at the Joint Commission Infection Control Conference on August 21 in Crystal City, Va.
Diabetes education significantly improves outcomes among people with the condition, leading to reduced blood sugar, blood pressure and cholesterol levels, according to data presented by the Diabetes Self-Management Education Program from New York-Presbyterian Hospital today at AADE14, the American Association of Diabetes Educators Annual Meeting & Exhibition.
Researchers have developed a novel test that identifies individuals who are the most likely to experience negative health effects if they eat a high salt diet.
The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
› Verified 3 days ago
| Entity Name | Iowa Physicians Clinic Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366425274 PECOS PAC ID: 8729992318 Enrollment ID: O20031118000363 |
News Archive
Premier healthcare alliance's Gina Pugliese, vice president of Premier's Safety Institute, will share insights on safe injection practices to improve patient and worker safety at the Joint Commission Infection Control Conference on August 21 in Crystal City, Va.
Diabetes education significantly improves outcomes among people with the condition, leading to reduced blood sugar, blood pressure and cholesterol levels, according to data presented by the Diabetes Self-Management Education Program from New York-Presbyterian Hospital today at AADE14, the American Association of Diabetes Educators Annual Meeting & Exhibition.
Researchers have developed a novel test that identifies individuals who are the most likely to experience negative health effects if they eat a high salt diet.
The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jasmin R Cabrera, MD 3740 Utica Ridge Rd, Suite B, Bettendorf, IA 52722-1657 Ph: (563) 344-7400 | Dr Jasmin R Cabrera, MD 3740 Utica Ridge Rd, Suite B, Bettendorf, IA 52722-1657 Ph: (563) 344-7400 |
News Archive
Premier healthcare alliance's Gina Pugliese, vice president of Premier's Safety Institute, will share insights on safe injection practices to improve patient and worker safety at the Joint Commission Infection Control Conference on August 21 in Crystal City, Va.
Diabetes education significantly improves outcomes among people with the condition, leading to reduced blood sugar, blood pressure and cholesterol levels, according to data presented by the Diabetes Self-Management Education Program from New York-Presbyterian Hospital today at AADE14, the American Association of Diabetes Educators Annual Meeting & Exhibition.
Researchers have developed a novel test that identifies individuals who are the most likely to experience negative health effects if they eat a high salt diet.
The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
› Verified 3 days ago
Dr. Daniel J Arnold, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4480 Utica Ridge Rd Ste 160, Bettendorf, IA 52722 Phone: 563-742-4850 Fax: 563-742-4855 | |
Dr. Michael J Gimbel Ii, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4017 Devils Glen Rd, Ste 100, Bettendorf, IA 52722 Phone: 563-332-6387 Fax: 563-332-9197 | |
Dr. Mary Ann Defrance, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2140 53rd Ave, Bettendorf, IA 52722 Phone: 563-421-5700 | |
Christopher M Crome, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2140 53rd Ave, Bettendorf, IA 52722 Phone: 563-421-5700 Fax: 563-421-5839 | |
Emmett Lee Wallace, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1019 Broadlawn Avenue, Bettendorf, IA 52722 Phone: 563-359-1181 Fax: 563-386-3177 | |
Sara Glassgow, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 2730 Crow Creek Rd, Bettendorf, IA 52722 Phone: 954-399-4673 Fax: 815-454-2832 |